Immunome

Immunome

IMNM· Manufacturing· Fiscal year ends in December

CEO pay in FY2024Stock -0.7% in FY2024

Clay Siegall, Ph.D. is the CEO of Immunome and was paid $9.2M in FY2024 (Dec), down 38%.

Pay$100 in the stock at the end of FY22 → $481
CEO pay is from each Immunome proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Clay Siegall, Ph.D.FY2024
  2. 2Robert Lechleider, M.D.FY2023
  3. 3Max RosettNot disclosed

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Immunome paid its 3 named executives $21.5M in total in FY2024 (Dec). CEO Clay Siegall, Ph.D. was paid $9.2M of that.

Name
Clay Siegall, Ph.D.President, Chief Executive Officer and Chairman of the BoardNot disclosed
Robert Lechleider, M.D.Chief Medical OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Immunome. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board1

See all
  • Carol SchaferDirector · 1 yr on the boardIndependentAudit (Chair), Nominating—Paid as an executive

The board of the latest proxy (FY2025).

Shared directors

Activity

Filings6

See all
Proxy statementDEF 14AApr 24, 2026FY2025
Annual report10-KMar 3, 2026FY2025
Proxy statementDEF 14AApr 24, 2025FY2024
Annual report10-KMar 19, 2025FY2024
Proxy statementDEF 14AApr 26, 2024FY2023
Annual report10-KMar 28, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data